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Abstract 32 
Neuroimaging studies in schizophrenia have linked elevated glutamate metabolite levels to non-remission 33 
following antipsychotic treatment, and also indicate that antipsychotics can reduce glutamate metabolite 34 
levels. However, the relationship between symptomatic reduction and change in glutamate during initial 35 
antipsychotic treatment is unclear. Here we report proton magnetic resonance spectroscopy (1H-MRS) 36 
measurements of Glx and glutamate in the anterior cingulate cortex (ACC) and thalamus in patients with 37 
first episode psychosis (n=23) at clinical presentation, and after 6 weeks and 9 months of treatment with 38 
antipsychotic medication. At 9 months, patients were classified into Remission (n=12) and Non-Remission 39 
(n=11) subgroups. Healthy volunteers (n=15) were scanned at the same three time-points. In the thalamus, 40 
Glx varied over time according to remission status (P=0.020). This reflected an increase in Glx between 6 41 
weeks and 9 months in the Non-Remission subgroup that was not evident in the Remission subgroup 42 
(P=0.031). In addition, the change in Glx in the thalamus over the 9 months of treatment was positively 43 
correlated with the change in the severity of Positive and Negative Syndrome Scale (PANSS) positive, total 44 
and general symptoms (P<0.05). There were no significant effects of group or time on glutamate 45 
metabolites in the ACC, and no differences between either patient subgroup and healthy volunteers. These 46 
data suggest that the nature of the response to antipsychotic medication may be related to the pattern of 47 
changes in glutamatergic metabolite levels over the course of treatment. Specifically, longitudinal 48 
reductions in thalamic Glx levels following antipsychotic treatment are associated with symptomatic 49 
improvement.  50 
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Introduction  51 
In around one third of patients with schizophrenia, treatment with antipsychotic medication is ineffective1–52 
3, but the underlying neurobiological mechanisms of treatment response are not well understood. 53 
Schizophrenia is associated with disruptions in brain glutamatergic neurotransmission4,5, and recent 54 
neuroimaging studies have indicated that the nature of the antipsychotic response may be related to brain 55 
glutamate levels6–11. In patients with first episode psychosis prior to treatment, elevated glutamate in the 56 
anterior cingulate cortex (ACC) have been associated with a lower likelihood of reaching remission after 4 57 
weeks of amisulpride8. Similarly, in established schizophrenia, higher levels of Glx (the combined signal 58 
from glutamate plus glutamine) in the medial frontal cortex have been associated with a poor response 59 
after restarting antipsychotic medication10. Elevated ACC glutamatergic metabolites have also been 60 
reported in first episode patients who had failed to achieve remission following antipsychotic treatment7, 61 
in patients who were treatment resistant6,9 and in patients resistant to clozapine12. Elevated glutamate 62 
metabolites in treatment-resistant schizophrenia have also been described in the caudate nucleus11.   63 
 64 
While brain glutamate metabolite levels have thus been related to antipsychotic response8, levels of these 65 
metabolites may be reduced by antipsychotic medication13. In patients with first episode psychosis, 66 
longitudinal reductions in glutamate in the ACC and left thalamus have been observed over 4 weeks of 67 
antipsychotic treatment8, and longitudinal reductions in glutamine and Glx in the left thalamus have been 68 
reported after 30 and 80 months of treatment14,15. Glutamate reductions have also been reported in the 69 
frontal cortex, following 4 and 6 months of antipsychotic treatment16–18, and in the striatum following 4 70 
weeks of antipsychotic treatment18,19. However, reductions in glutamatergic metabolites in the thalamus20 71 
or ACC20,21 have not been detected by other studies. Studies in patients with chronic schizophrenia have 72 
produced mixed findings, some reporting reductions in glutamate levels following antipsychotic treatment 73 
in the frontal22 and temporal cortex23, but others finding no change (in frontal cortex23–25, temporal cortex25 74 
and thalamus23,25).  75 
 76 
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If there are longitudinal reductions in glutamate levels with antipsychotic treatment, we hypothesised that 77 
these may be related to symptomatic improvement. The present study aimed to test this by examining the 78 
relationship between glutamate metabolites in the ACC and thalamus and remission status at three 79 
timepoints over the first 9 months of antipsychotic treatment in patients with first episode psychosis. The 80 
present dataset is an extension to our previous study, which investigated the relationship between 81 
glutamate and treatment response over 4 weeks, reporting that elevated glutamate in the ACC at first 82 
presentation predicted poor antipsychotic response8. Here we extend to a longer follow-up period of 9 83 
months in a subset of this cohort. This duration of treatment corresponds to that in our previous cross-84 
sectional study, which found that after 9 months of treatment, first episode patients who had not achieved 85 
remission had higher ACC glutamate levels than those in remission7. To aid interpretation of our findings, 86 
we also assessed a sample of healthy volunteers over the same time period.  87 
 88 
Results 89 
At 9 months, 12 patients met Remission criteria and 11 patients met criteria for Non-Remission. There 90 
were no significant differences in demographic variables between the Remission and Non-Remission 91 
subgroups, in substance use (Supplementary Table 1) or in duration of or adherence to antipsychotic 92 
medication at any timepoint (Table 1 and Supplementary Notes).  At the time of the baseline scan, 4 93 
patients were medication naïve, and all but one of the remaining patients were receiving amisulpride. At 94 
the 6 weeks and 9 month timepoint the Remission and Non-Remission groups were taking a similar set of 95 
antipsychotic drugs, and did not differ in chlorpromazine equivalent dose (Table 1). Please see Table 1 and 96 
Supplementary Notes for group differences in PANSS scores at each timepoint. 97 
 98 
Variables relating to 1H-MRS data quality are provided in Supplementary Table 2. For one patient Glx and 99 
glutamate data from the thalamus were below 20% CRLB, reducing the sample to n=22, and for one 100 
healthy volunteer Glx data from the thalamus were below 20% CRLB, reducing the sample to n=14. There 101 
were no significant group differences for spectra quality (Supplementary Table 2) or voxel tissue content 102 
(Table 2). 103 
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 104 
For both Glx and Glutamate in the ACC, there were no significant main or interaction effects of remission 105 
status or time (Figure 1, Supplementary Table 3). This was also the case when time to follow-up was 106 
included as a covariate, and when analysis was restricted to patients who were adherent to antipsychotic 107 
medication at least 75% of the time. There were no significant relationships between the longitudinal 108 
percentage change in ACC glutamatergic metabolites and the percentage change in symptoms over time 109 
(Supplementary Table 4). There was also no significant difference in ACC glutamate metabolite levels over 110 
time in healthy volunteers compared to the overall patient sample (Figure 2). 111 
 112 
Glx levels in the left thalamus showed a significant interaction between remission status and time 113 
(F(2,40)=4.337, P=0.020, repeated measures ANOVA, Figure 1). The main effects of remission status 114 
(F(1,20)=0.121, P=0.731) and time (F(2,40)=2.541, P=0.091) were non-significant. At 9 months Glx levels in 115 
the thalamus were significantly higher in the Non-Remission compared to Remission group (F(1,20)=5.244, 116 
P=0.033, Cohen’s d=0.98, one-way ANOVA). This was related to a significant effect of time in the Non-117 
Remission group (F(2,20)=6.183, P=0.008, repeated measures ANOVA), which reflected an increase in Glx 118 
concentration between 6 weeks and 9 months (P=0.031, Cohen’s d=1.24, Bonferroni-corrected pairwise 119 
comparisons). Within the Remission subgroup, Glx levels did not vary significantly over time 120 
(F(2,20)=1.849, P=0.183, repeated measures ANOVA). Similar results were obtained when the analysis was 121 
restricted to patients who reported being medication adherent at least 75% of the time (Supplementary 122 
Figure 2). There were no significant differences in thalamic Glx levels over time in the healthy volunteer 123 
group compared to the overall patient sample (Figure 2, Supplementary Table 3).  124 
 125 
Glutamate levels in the left thalamus showed a significant effect of time (F(2,40)=7.306, P=0.002, repeated 126 
measures ANOVA), while the main effects of remission status (F(1,20)=0.036, P=0.852) and the remission 127 
status x time interaction were not significant (F(2,40)=1.310, P=0.281, Figure 1). The effect of time 128 
reflected a significant decrease in thalamic glutamate across both patient subgroups between baseline and 129 
6 weeks (P=0.005, Bonferroni-corrected pairwise comparisons), and a significant increase between 6 weeks 130 
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and 9 months (P=0.010, Cohen’s d=-0.67). The results remained the same when the analysis was restricted 131 
to patients who were adherent to antipsychotic medication at least 75% of the time. When the entire 132 
patient sample was compared to the healthy volunteer sample, the effect of time on glutamate in the 133 
thalamus was apparent across all subjects (healthy volunteers and patients) (F(2,70)=3.753, P=0.028, 134 
repeated measures ANOVA), and was related to a significant decrease in glutamate between baseline and 135 
6 weeks (P=0.045, Cohen’s d=-0.52, Bonferroni-corrected pairwise comparisons, Figure 2). No significant 136 
effect of diagnostic group, and no interaction were found (Supplementary Table 3). 137 
 138 
There was a positive correlation between the percentage change in Glx levels in the thalamus and the 139 
percentage change in PANSS positive score between baseline and 9 months (r=.512, P=0.015, Pearson’s 140 
bivariate correlation): the greater the longitudinal reduction in thalamic Glx, the greater the improvement 141 
in positive symptoms over the course of treatment (decrease in PANSS positive score). This correlation 142 
remained significant when one outlying value identified using Cook’s D was excluded (r=.493, P=0.023, 143 
Figure 3). Secondary analyses found positive correlations between the percentage change in Glx in the 144 
thalamus and the percentage change in PANSS general (r=.446, P=0.037) and PANSS total (r=.501, P=0.018) 145 
scores, but not the PANSS negative score (r=-.053, P=0.815, Figure 3) or PSP score (r=-.135, P=0.550). 146 
Relationships remained significant when partial correlations were conducted to control for time to follow-147 
up. 148 
 149 
In contrast, there were no significant relationships between the percentage change in glutamate in the 150 
thalamus and percentage symptom change (Supplementary Table 4).  151 
 152 
Repeated measures MANOVA analyses assessed metabolite changes over time for N-acetyl-aspartate, 153 
creatine, myo-inositol, and choline (Supplementary Table 5). There were no significant main effects of 154 
group, time or interaction in remission versus non-remission groups in the ACC or left thalamus, or in 155 
patients versus healthy volunteers in the ACC. In the thalamus, there was a significant interaction between 156 
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group (patient vs healthy volunteer) and time (F(2,70)=3.520, P=0.010). Post-hoc tests did not find 157 
significant effects when groups and timepoints were analysed separately. 158 
 159 
Discussion 160 
This study investigated the relationship between brain glutamatergic metabolites and the response to 161 
antipsychotic medication over the first 9 months of treatment for psychosis. The main finding was that Glx 162 
in the thalamus increased over time in Non-Remitters, such that after 9 months Glx levels were higher in 163 
patients who were not in remission than in those who were. Furthermore, symptomatic improvement over 164 
the course of treatment was associated with a longitudinal reduction in thalamic Glx levels. These results 165 
extend our previous observations over shorter periods of treatment8 to indicate that longer-term 166 
symptomatic response may be linked to the level of glutamatergic metabolites.  167 
 168 
In a recent longitudinal study over 4 weeks of antipsychotic treatment (containing an overlapping sample 169 
of the participants to the current study) we also found that glutamate levels decreased over time in the 170 
thalamus, but there was no significant relationship between the reduction over this timeframe and 171 
symptomatic improvement8.  In this extended study, the treatment period was 9 months, which suggests 172 
that longitudinal differences in relation to symptomatic response may emerge after longer periods of 173 
treatment. This 9 month period is comparable to the time since presentation in an earlier cross sectional 174 
study in first episode psychosis, in which we also observed numerically but non-significantly higher 175 
thalamic Glx in the Non-Remission compared to Remission group7.  176 
 177 
The results of the present study are broadly consistent with a previous report in patients with 178 
schizophrenia showing that higher social and occupational functioning scores 80 months after diagnosis 179 
are associated with a greater degree of thalamic Glx reduction over those 80 months14. Together these 180 
findings suggest that thalamic Glx levels may be more related to symptomatic outcome after a period of 181 
several months, rather than the initial period of treatment. A recent study observed a trend for an increase 182 
in thalamic Glx levels over 5 years in first episode psychosis patients, although the relationship with 183 
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treatment response was not investigated34. At 9 months, there were no group differences in substance use 184 
or spectral quality. However, there was a numerically higher percentage of cannabis users in the non-185 
remission group, with a higher frequency of use. It is possible that cannabis use or other unknown external 186 
factors may have contributed to the observed increase in thalamic Glx in non-remitters35.    187 
 188 
Thalamocortical dysconnectivity is thought to be a key pathophysiological feature of schizophrenia36, and 189 
may be mediated by alterations in thalamic glutamatergic transmission37,38.  Human neuroimaging studies 190 
have demonstrated that antipsychotic administration can modify thalamic activity and metabolism39–42, but 191 
there are fewer data on the role of the thalamus and its cortical connectivity in mediating clinical outcome, 192 
with some studies43–45 but not others42,46 suggesting an association. This could be explored in future work 193 
combining serial 1H-MRS glutamate and functional connectivity measurements in relation to early and 194 
longer-term clinical outcomes.  195 
 196 
Contrary to our expectations, we did not detect any significant relationships between remission status and 197 
glutamatergic metabolite levels in the ACC. This is inconsistent with most previous reports linking  198 
antipsychotic non-response to elevated glutamate in the ACC6–10,12, although one other study did not 199 
detect differences in ACC glutamate in relation to response11. In our recent study that involved a larger 200 
sample (n=46) overlapping with the present cohort8, non-remission at 4 weeks was associated with 201 
elevated ACC glutamate prior to treatment with amisulpride. The lack of significant difference in the 202 
current smaller sample (n=23) may reflect limitations of sample size. In addition, compared to our larger 203 
study8, a greater proportion of participants in the present study had received antipsychotics prior to 204 
baseline, which may have affected ACC glutamate metabolite levels13.  205 
 206 
In line with data from previous studies5,8,21, we did not detect significant differences in thalamic or ACC Glx 207 
or glutamate concentrations between the total patient sample and healthy volunteers. Although a recent 208 
meta-analysis of the literature suggests that there may be differences between first episode patients and 209 
healthy volunteers in glutamine levels in the thalamus and ACC5, the acquisition parameters we used at 3 210 
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Tesla did not allow reliable quantification of glutamine. While Glx in the thalamus increased over time in 211 
Non-Remitters, this effect did not reach significance for the glutamate signal alone. This may relate to 212 
differences in the Glx versus glutamate measurement, or could indicate that glutamine is contributing to 213 
this effect.  214 
 215 
A strength of this study is the relatively long follow-up period of 9 months in comparison to most previous 216 
studies16,19,22,23,25,47 which, together with scanning early in treatment permitted investigation of the 217 
relationships between brain glutamate and short and longer term outcome under antipsychotic treatment. 218 
A further strength is sample homogeneity, through the inclusion of participants in their first episode of 219 
psychosis who had received minimal prior antipsychotic medication.  220 
 221 
One limitation of the study was that the majority of participants were not antipsychotic naïve at baseline 222 
and may have already experienced initial symptomatic improvement. Even short-term antipsychotic 223 
exposure may reduce glutamate levels8 and may have reduced our ability to detect subsequent reductions. 224 
The 52% response rate in the present sample is slightly lower than that reported in the literature in first 225 
episode psychosis (approximately 60%26,48–50), which may be accounted for by prior medication exposure, 226 
or by the longer follow-up time period. Other limitations include controlling for the potential effects of 227 
medication adherence, which was estimated through self-report and clinical notes. Although the findings 228 
remained significant when the analysis was restricted to participants who reported being medication 229 
adherent at least 75% of the time, inclusion of more accurate measures of adherence, such as 230 
antipsychotic plasma levels, would have been helpful. The majority of patients initially received the same 231 
antipsychotic medication, amisulpride, which is a relatively selective D2 dopamine receptor antagonist51. 232 
However, subsequently there was more variation in the particular antipsychotic medications used. 233 
Differences in the pharmacological profile of antipsychotics could have differential effects on glutamatergic 234 
neurotransmission52, which may have increased variability over the observation period. Nevertheless, at 235 
the 9 month timepoint, the Remission and Non-Remission groups were taking a similar set of antipsychotic 236 
drugs, the levels of medication adherence were comparable, and a similar proportion of patients were no 237 
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longer taking medication. The data also showed a reduction in thalamic glutamate across all participants 238 
between baseline and 6 weeks, which may reflect a methodological factor impacting on the measurement. 239 
This indicates the utility of including a healthy volunteer or other non-intervention group for interpretation 240 
of longitudinal studies. Lastly, this study used adapted Andreasen’s criteria for remission, consistent with 241 
previous studies7,26. Therefore our study did not account for fluctuations in symptoms or remission status 242 
that may have occurred over the 9 month period, which would require regular symptom monitoring.  243 
 244 
In summary, the findings of the present study extend the literature linking ACC glutamate to antipsychotic 245 
response6–10 by indicating that response to antipsychotic medication over the first 9 months of treatment 246 
may be related to longitudinal changes in glutamatergic metabolites in the thalamus. The association 247 
between elevated thalamic Glx levels and Non-Remission is consistent with the notion that brain glutamate 248 
transmission is a potential therapeutic target for novel treatments for psychosis.  249 
 250 
Methods 251 
The study included participants recruited in two studies: OPTiMiSE (Optimisation of Treatment and 252 
Management of Schizophrenia in Europe; www.optimisetrial.eu; EudraCT-Number: 2010-020185-19; 253 
clinicaltrials.gov identifier: NCT0124819526) (n=34, using the London sample from the OPTiMiSE study8), 254 
and TRFEP (The neurobiological determinants of treatment response in psychosis27) (n=6, with an 255 
additional n=3 taking part in both studies). Both studies were granted ethical approval by the South 256 
London and Maudsley NHS Trust Ethics Committee, and all participants provided written informed 257 
consent. Patients were recruited from early intervention community teams and wards. We aimed to recruit 258 
24 participants to detect a change in Glx levels with antipsychotic treatment, according to power 259 
calculations reported in a recent meta-analysis13. Of 43 patients who agreed to participate in the study, a 260 
total of n=23 patients completed all 3 scans (n=14 from the OPTiMiSE study, n=6 from the TRFEP study, 261 
and n=3 taking part in both studies) (Supplemental Figure 1). In the patient group, inclusion required 262 
presentation with a first episode of psychosis within the past 2 years, aged between 18-40, and a diagnosis 263 
of a psychotic disorder according to ICD 10 criteria or DSM-IV criteria. Inclusion required previous 264 
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antipsychotic exposure of <15 days (OPTiMiSE study), or no exposure to antipsychotic medication within 265 
the past 6 weeks (TRFEP study). Exclusion criteria included being unable to provide written informed 266 
consent, being coercively treated or being under legal custody. Healthy volunteers (n=36) were recruited 267 
through online advertisements, with n=15 completing all three MRI sessions. Healthy volunteers were 18-268 
40 years old with no history of psychiatric illness. All subjects had no history of head injury or 269 
contraindications to MRI scanning.  270 
 271 
In the patient sample, symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS)28, 272 
and functioning was assessed using the Personal and Social Performance (PSP) scale at each MRI scan visit. 273 
Medication adherence and illicit drug use was determined using clinical notes and self-report of dates 274 
when medication was taken. Chlorpromazine Equivalent Doses were calculated29. The primary clinical 275 
outcome measure was remission at 9 months, based upon adapted Andreasen criteria30, consistent with 276 
our larger study26, and previous cross-sectional study in first episode psychosis7.  277 
 278 
MRI scans were conducted at baseline and repeated after a mean of 6 weeks and 9 months. All data were 279 
acquired at 3-Tesla on a General Electric Healthcare (Chicago, USA) HDxt MR system. The same sequences 280 
were acquired at each time-point.  Whole brain sagittal T1-weighted images were acquired using a 281 
modified ADNI GO protocol (See http://adni.loni.usc.edu/methods/documents/mri-protocols/) with an 282 
echo time (TE) 2.848 ms; repetition time(TR) 6.984 ms; inversion time 400 ms; flip angle 11°, Field of view 283 
260mm, slice thickness 1.2mm, matrix size 256x256mm. The structural images were reformatted to axial 284 
orientation for 1H-MRS voxel positioning in the bilateral ACC and left thalamus. The centre of the ACC 285 
voxel (20 x 20 x 20 mm) was positioned 16mm superior to the anterior portion of the genu of the corpus 286 
callosum on the midline sagittal localiser, avoiding the corpus callosum. The voxel in the left thalamus (15 x 287 
20 x 20 mm) was also positioned from the axial image, using the coronal and sagittal localisers to minimise 288 
cerebrospinal fluid (CSF) content in the voxel (voxel placement and example spectra previously published8).  289 
 290 
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1H-MRS spectra were acquired using PRESS (Point RESolved Spectroscopy), at TE = 30 msec; TR = 3000 291 
msec; 96 averages; bandwidth / sample frequency = +/- 2500Hz; number of complex points  = 4096. Data 292 
were acquired using the standard GE PROBE (PROton Brain Examination) sequence, which includes 293 
acquisition of unsuppressed water reference spectra (16 averages). The target water line-widths after 294 
shimming were < 7Hz in the ACC and < 10Hz in the left thalamus. For follow-up scans, radiographers 295 
referred to the baseline scan voxel position to reduce variability in voxel placement.  296 
 297 
Spectra were analyzed using LC Model version 6.3-0I31,32 using a standard LC Model basis set acquired using 298 
PRESS at 3-Tesla and a TE of 30msec containing 16 metabolites. Poorly fitted metabolite peaks (Cramer–299 
Rao lower variance bounds (CRLB) >20% as reported by LCModel) were excluded from further analysis. All 300 
metabolite values are reported in institutional units. 301 
 302 
To correct metabolite concentration estimates for voxel CSF content, T1-weighted images were segmented 303 
into grey matter, white matter and CSF images using Statistical Parametric Mapping 8, version 6313 (SPM8; 304 
Wellcome Department of Imaging Neurosciences, University College London, UK). Voxel coordinates were 305 
obtained from spectra file headers using General Electric’s spectroscopy processing tool SAGE and mapped 306 
against the T1-weighted structural images using in-house software, to calculate the percentage tissue 307 
content of the individual 1H-MRS voxels. Metabolite values were then corrected using the following 308 
equation32: 309 
Uncorrected metabolite x (wm+ 1.21 x gm + 1.55 x csf) / (gm+wm) 310 
gm = grey matter  311 
wm =white matter 312 
csf = cerebrospinal fluid 313 
 314 
Statistical analyses were performed using SPSS version 23 (SPSS inc. Chicago, Illinois, USA). For 315 
demographic and clinical data, between group differences were assessed using Fisher’s Exact Test (2 tailed) 316 
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and independent samples Student’s t-test. Equal variances were assumed unless Levene’s test was 317 
significant.  318 
 319 
The main 1H-MRS metabolites of interest were Glx and glutamate, corrected for voxel CSF content.  320 
Repeated measures ANOVA assessed the effects of time, group and group*time on voxel Glx and 321 
glutamate levels. A significant effect of time was followed up with Bonferroni-corrected pairwise 322 
comparisons (to determine significant differences between timepoints). A significant effect of group was 323 
followed up by one-way ANOVA tests (to determine group differences at separate timepoints). A 324 
significant interaction was followed up with one-way ANOVA tests, and also a repeated measures ANOVA 325 
in the remission and in the non-remission groups separately, with Bonferroni-corrected pairwise 326 
comparisons (to determine significant differences between timepoints in each group seperately). The 327 
primary analysis compared the Remission and Non-Remission patient groups.  Subsequent analyses 328 
compared the healthy volunteer group to the total patient group.  Relationships between the percentage 329 
change in PANSS score (minus minimum possible scores)33 or PSP score, and the percentage change in Glx 330 
and glutamate over 9 months were assessed using Pearson’s bivariate correlations (2 tailed). Outliers were 331 
identified using Cook’s distance estimates, excluding values higher than 4/n. Repeated measures MANOVA 332 
assessed metabolite changes over time for other metabolites. The data that support the findings of this 333 
study are available from the corresponding author upon reasonable request. 334 
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Figure legends 493 
Figure 1 Glx (left) and Glutamate (right) at Baseline, 6 weeks and 9 months, in Remission and Non-Remission groups in A) 494 
Anterior Cingulate Cortex and B) Left Thalamus *Represents higher thalamic Glx levels in the Non-Remission group compared to 495 
the Remission group at 9 months (P=0.033). Glx and glutamate values are CSF-corrected, presented as mean & within-subjects 496 
standard deviation.   497 
Figure 2 Glx (left) and Glutamate (right) at Baseline, 6 weeks and 9 months, in First Episode Psychosis (FEP) patients and Healthy 498 
Volunteers in A) Anterior Cingulate Cortex and B) Left Thalamus.  499 
Figure 3 Correlations between change in PANSS score (-100% indicates full symptomatic improvement, whereas 0% denotes no 500 
change in symptoms) and change in thalamic Glx levels over 9 months (negative values indicate reduction in thalamic Glx levels, 501 
whereas positive values indicate increase in thalamic Glx). A) Significant positive correlation between the percentage change in 502 
Glx levels in the thalamus and the percentage change in PANSS positive score (r=.493, P=0.023), B) PANSS total (r=.501, P=0.018) 503 
score and C) PANSS general score (r=.446, P=0.037), between baseline and 9 months. D) No significant correlation for the 504 
percentage change in PANSS negative score.  505 
 506 
Table 1 Subject demographics and clinical characteristics. Mean and (Standard Deviation) presented. Remission and Non-507 
Remission groups were classified based on presentation at the 9 month timepoint. Significant differences between Healthy 508 
Volunteers and FEP patients are denoted by *=P<0.05, ** = P<0.01, *** = P<0.001 in the FEP patient column; significant 509 
differences between the Remission and Non-Remission group are denoted in the Remission group column. FEP; First episode 510 
psychosis, PANSS; Positive And Negative Syndrome Scale, PSP; Personal and Social Performance scale; CPZ Equivalent Dose; 511 
Chlorpromazine Equivalent Dose. 512 
Table 2 1H-MRS metabolite concentrations corrected for voxel cerebrospinal fluid (CSF) content, and 1H-MRS voxel % of white 513 
matter, grey matter and CSF, at three timepoints. Data are presented as mean (SD). Significant group differences are represented 514 
by *=P<0.05. Glutamate (Glu), N-acetyl-aspartate (NAA), creatine (Cr), myo-inositol (mI), choline (Cho). 515 
 516 
 517 
 518 
